Data_Sheet_1_Comparison of the Clinical Value of miRNAs and Conventional Biomarkers in AMI: A Systematic Review.docx

Background/Aims: This study aimed to compare the clinical value of the peak time point and area under the curve (AUC) of miRNAs and conventional biomarkers in acute myocardial infarction (AMI).Methods: A literature search was carried out in PubMed, Web of Science, Embase, and Cochrane systematically. Screening studies, extracting data, and assessing article quality were performed independently by two researchers. Also, the names of miRNAs in the included studies were standardized by the miRBase database.Results: A total of 40 studies, encompassing 6,960 participants, were included in this systematic review. The samples of circulating miRNAs were mainly from the plasma. The results of this systematic review displayed that miR-1-3p, miR-19b-3p, miR-22-5p, miR-122-5p, miR-124-3p, miR-133a/b, miR-134-5p, miR-150-5p, miR-186-5p, miR-208a, miR-223-3p, miR-483-5p, and miR-499a-5p reached peak time earlier and showed a shorter time window than the conventional biomarkers despite the different collection times of initial blood samples. miR-1-3p, miR-19b-3p, miR-133a/b, miR-208a/b, miR-223-3p, miR-483-5p, and miR-499a-5p were shown to be more valuable than classical biomarkers for the early diagnosis of AMI, and these miRNAs appeared to have the most potential biomarkers within 4 h of the onset of symptoms except miR-133a/b and miR-208b. Moreover, combined miRNAs or miRNAs combined with classical biomarkers could compensate for the deficiency of single miRNA and conventional biomarker in sensitivity or specificity for an optimal clinical value.Conclusions: miR-1-3p, miR-19b-3p, miR-208a, miR-223-3p, miR-483-5p, and miR-499a-5p are promising biomarkers for AMI due to their satisfactory diagnostic accuracy and short time window (within 4 h of the onset of symptoms).

背景/目的：本研究旨在比较miRNA的峰值时间点及其曲线下面积（AUC）与常规生物标志物在急性心肌梗死（AMI）临床价值上的差异。方法：在PubMed、Web of Science、Embase和Cochrane数据库中进行了系统文献检索。由两名研究者独立进行筛选研究、数据提取和文章质量评估。此外，纳入研究中miRNA的名称通过miRBase数据库进行了标准化。结果：共纳入40项研究，涉及6,960名参与者。循环miRNA样本主要来自血浆。系统评价结果显示，尽管首次采集血液样本的时间不同，miR-1-3p、miR-19b-3p、miR-22-5p、miR-122-5p、miR-124-3p、miR-133a/b、miR-134-5p、miR-150-5p、miR-186-5p、miR-208a、miR-223-3p、miR-483-5p和miR-499a-5p的峰值时间出现较早，且其时间窗口短于常规生物标志物。miR-1-3p、miR-19b-3p、miR-133a/b、miR-208a/b、miR-223-3p、miR-483-5p和miR-499a-5p在AMI的早期诊断中显示出比经典生物标志物更高的价值，并且这些miRNA在症状出现后4小时内显示出最大的生物标志物潜力（除miR-133a/b和miR-208b外）。此外，联合miRNA或miRNA与经典生物标志物的结合可以弥补单一miRNA和常规生物标志物在敏感度或特异性方面的不足，从而实现最佳的临床价值。结论：miR-1-3p、miR-19b-3p、miR-208a、miR-223-3p、miR-483-5p和miR-499a-5p因其令人满意的诊断准确性和短暂的时间窗口（症状出现后4小时内）而成为AMI的有希望的生物标志物。